Doximity stock hits 52-week low at 47.65 USD

Doximity Inc's stock reached a new 52-week low, trading at 47.65 USD. This milestone reflects the challenges the company has faced over the past year, with its stock experiencing a decline of 8.16% in the same period. According to InvestingPro data, technical indicators suggest the stock is currently in oversold territory, potentially signaling a buying opportunity for value investors. The company's performance in the market has been under scrutiny as investors assess its long-term growth potential amidst a competitive digital health landscape. Despite market pressures, Doximity maintains impressive financial fundamentals with a 90.2% gross profit margin and 20.21% revenue growth over the last twelve months. The company also holds more cash than debt on its balance sheet, with a robust current ratio of 7.79. InvestingPro analysis indicates the stock is trading below its Fair Value, with analyst price targets ranging from 55 to 83 USD. Discover 10+ additional ProTips and comprehensive analysis in the Pro Research Report, available exclusively to subscribers.

In other recent news, Doximity Inc. reported its Q2 FY2026 earnings, surpassing Wall Street expectations. The company announced an earnings per share (EPS) of $0.45, which exceeded the forecasted $0.38, resulting in an 18.42% surprise. Revenue for the quarter reached $168.5 million, also beating the anticipated $157.1 million. Despite these strong financial results, Doximity's stock experienced a decline in after-hours trading, closing at $63.80. This reaction from investors was influenced by the company's future guidance and prevailing market conditions. These developments highlight the importance of earnings and revenue information for investors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.